The active pharmaceutical ingredient (API) manufacturer, which provides contract development and production services to help firms fast-track drug candidates from discovery into Phase I/II GMP API manufacturing, achieved a £3.7m ($6m) turnover in the last year and also boosted staff numbers from 37 to 43.
The chemistry expert has bounced back from a challenging previous year that saw a significant drop in activity from the global drug development market alongside the general economic downturn.
Dr Tony Flinn, chief executive officer at Onyx Scientific, said: “We have had a very encouraging year in terms of sales growth and this gives us a solid foundation to now drive the business forward and expand.”
Now in its eleventh year of trading, Onyx Scientific provides outsourced facilities and expertise to help life science companies. It now works as a preferred partner of around half of the world’s top 10 pharma firms alongside a further 150 companies.
“Although 96% of our clients use our services on a repeat basis, we are placing great emphasis on service development, sales and marketing over the next year to acquire new clients. If we continue to deliver projects to a consistently high standard and meet all-important client timelines, we will keep heading in the right direction,” added Dr Flinn.